Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care
Open Access
- 1 September 2017
- journal article
- review article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 37 (5), 1371-1387
- https://doi.org/10.1148/rg.2017170015
Abstract
This article provides a comprehensive review of the thoracic complications of precision cancer therapies, with an emphasis on emerging challenges resulting from novel therapies such as immune checkpoint inhibitor therapies, and serves as a practical reference guide for radiologists. Recent advances in understanding the molecular mechanisms of cancer have opened a new era of precision medicine for cancer treatment. Precision cancer therapies target specific molecules that are responsible for cancer development and progression, and they achieve marked treatment benefits in specific cohorts of patients. However, these therapies are also associated with a variety of complications that are often unique to specific groups of anticancer agents. The rapidly increasing use of immune checkpoint inhibitors in the treatment of various advanced malignancies has brought new challenges in diagnosing and monitoring a unique set of toxic effects termed immune-related adverse events. Familiarity with cutting-edge cancer treatment approaches and awareness of the emerging complications from novel therapies are essential for radiologists, who play a key role in the care of patients with cancer. This article provides a comprehensive review of the thoracic complications of precision cancer therapies, descr...Funding Information
- National Cancer Institute (1R01CA203636, 5K23CA157631)
This publication has 77 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Non-infectious pulmonary toxicity of rituximab: a systematic reviewRheumatology, 2011
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer centerCancer, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Anti-CD20 monoclonal antibodies: historical and future perspectivesHaematologica, 2009
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimusEuropean Journal of Cancer, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004